TIME TO RECOVERY FOR PATIENTS HOSPITALIZED WITH COVID-19 REMDETAJ ™ (#remdesivir) reduced recovery time by 5 days.

TIME TO RECOVERY

FOR PATIENTS HOSPITALIZED WITH COVID-19

REMDETAJ ™ (#remdesivir) reduced recovery time

by 5 days in the ACTT-1 overall study population.

REMDESIVIR INJECTION IN LYOPHILIZED POWDER

100 MG, IS A STERILE, PRESERVATIVE-FREE AT

AFFORDABLE PRICES.

Remdesivir Available for Export!

#remdesivircoronavirus #remdésivir #remdesivirdrug #remdesivir100mg #remdesivir150mg #covid19 #REMDETAJ #REMDETAJ_remdesivir #tajpharmafightscorona #tajpharmafightscovid19 #tajpharmafightscovid

#remdesivirindia #coronavirus #strongertogether #coronavirusupdates #covidtreatment #importremdesivir #covid19lifesavingdrug

Remdesivir Available for Export!

Direct line: +91 8448 444 095

Toll free: 1-800-222-434

Toll free: 1-800-222-825

General EPA BX: +91 22 2637 4592

+91 22 2637 4593

Fax No.:+91 22 2634 1274

E-Mail: info@tajpharma.com

#remdesivircoronavirus #remdésivir #remdesivirdrug #remdesivir100mg #remdesivir150mg #covid19 #vidvir #vidvir_remdesivir #tajpharmafightscorona #tajpharmafightscovid19 #tajpharmafightscovid

#remdesivirindia #coronavirus #strongertogether #coronavirusupdates #covidtreatment #importremdesivir #covid19lifesavingdrug

COVID-19=coronavirus disease 2019; SARS-CoV-2=severe acute respiratory syndrome coronavirus 2.

*Seizure (n=1), infusion-related reaction (n=1).

†Seizure (n=1), infusion-related reaction (n=1), transaminases increased (n=3), ALT increased and AST increased (n=1), GFR decreased (n=2), acute kidney injury (n=3).

----------------------------------------------------------------------------------------

Adverse reactions

• The most common adverse reaction (≥5% all grades) was nausea.

• The most common lab abnormalities (≥5% all grades) were increases in ALT and AST.

Drug interactions

• Drug interaction trials of REMDETAJ and other concomitant medications have not been conducted in humans.

Dosage and administration

• Dosage: For adults and pediatric patients ≥12 years old and weighing ≥40 kg: 200 mg on Day 1, followed by once-daily maintenance doses of 100 mg from Day 2 administered only via intravenous infusion over 30 to 120 minutes.

• Treatment duration: For patients not requiring invasive mechanical ventilation and/or extracorporeal membrane oxygenation (ECMO): 5 days; may be extended up to 5 additional days (10 days total) if clinical improvement is not observed. For patients requiring invasive mechanical ventilation and/or ECMO: 10 days.

• Testing prior to and during treatment: Perform eGFR, hepatic laboratory, and prothrombin time testing prior to initiating REMDETAJ and during use as clinically appropriate.

• Renal impairment: REMDETAJ is not recommended in individuals with eGFR <30 mL/min.

IMPORTANT SAFETY INFORMATION

Contraindication

• REMDETAJ is contraindicated in patients with a history of clinically significant hypersensitivity reactions to REMDETAJ or any of its components.

Warnings and precautions

• Hypersensitivity, including infusion-related and anaphylactic reactions: Hypersensitivity, including infusion-related and anaphylactic reactions, has been observed during and following administration of REMDETAJ. Monitor patients under close medical supervision for hypersensitivity reactions during and following administration of REMDETAJ. Symptoms may include hypotension, hypertension, tachycardia, bradycardia, hypoxia, fever, dyspnea, wheezing, angioedema, rash, nausea, diaphoresis, and shivering. Slower infusion rates (maximum infusion time ≤120 minutes) can potentially prevent these reactions. If a severe infusion-related hypersensitivity reaction occurs, immediately discontinue REMDETAJ and initiate appropriate treatment (see Contraindications).

• Increased risk of transaminase elevations: Transaminase elevations have been observed in healthy volunteers and in patients with COVID-19 who received REMDETAJ; these elevations have also been reported as a clinical feature of COVID-19. Perform hepatic laboratory testing in all patients (see Dosage and administration). Consider discontinuing REMDETAJ if ALT levels increase to >10x ULN. Discontinue REMDETAJ if ALT elevation is accompanied by signs or symptoms of liver inflammation.

• Risk of reduced antiviral activity when coadministered with chloroquine or hydroxychloroquine: Coadministration of REMDETAJ with chloroquine phosphate or hydroxychloroquine sulfate is not recommended based on data from cell culture experiments, demonstrating potential antagonism, which may lead to a decrease in the antiviral activity of REMDETAJ.